Comparable stake leader
FMR LLC
SEC ownership of Immuneering Corp
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001790340.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- IMRX on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001790340
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Immuneering Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 14%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 14%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
14%
Benjamin J. Zeskind
6.6%
HBM Healthcare Investments (Cayma...
5.7%
Empery Asset Management, LP
5%
Sanofi
4.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
14%
|
$71,526,603
8,787,052 shares
|
$0 | 30 Sep 2025 |
| Benjamin J. Zeskind |
13D/G
3/4/5
PRESIDENT AND CEO, Director
|
6.6%
|
$28,674,370
4,357,807 shares
|
+$2,498,025 | 31 Dec 2025 |
| HBM Healthcare Investments (Cayman) Ltd. |
13D/G
|
5.7%
|
$29,680,915
3,646,304 shares
|
$0 | 26 Sep 2025 |
| Empery Asset Management, LP |
13D/G
|
5%
|
$20,154,805
3,250,775 shares
|
-$12,015,476 | 31 Dec 2025 |
| Sanofi |
13F
Company
|
4.1%
|
$14,274,106
2,708,559 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.5%
|
$12,059,557
2,288,341 shares
|
— | 31 Mar 2026 |
| MARSHALL WACE, LLP |
13F
Company
|
3%
|
$10,522,002
1,996,585 shares
|
— | 31 Mar 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
2.8%
|
$9,640,000
1,829,188 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$515,007.
Buys
$515,007
Insiders: 9
Sells
$0
Insiders: 0
Net
+$515,007
Shares: +108,074
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 108,074
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 8,435 | 0 | $35,993 | $0 | +$35,993 |
| 3-6 | 51,819 | 0 | $234,343 | $0 | +$234,343 |
| 6-9 | 22,120 | 0 | $152,642 | $0 | +$152,642 |
| 9-12 | 25,700 | 0 | $92,029 | $0 | +$92,029 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to Immuneering Corp. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Benjamin J. Zeskind
Net 12M change
+$515,006
Latest report
23 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Benjamin J. Zeskind | PRESIDENT AND CEO, Director | $15,277,750 | +$45,827 | +0.3% | Mixed | 23 Jun 2026 |
| Cormorant Asset Management, LP | 10%+ Owner | $8,598,961 | Filing P/S | 01 Apr 2024 | ||
| Peter Feinberg | Director | $6,947,380 | +$225,559 | +3.4% | Mixed | 11 Jun 2026 |
| Brett Matthew Hall | Chief Scientific Officer | $1,587,503 | +$35,547 | +2.3% | Filing P/S | 15 Jun 2026 |
| Thomas J. Schall | Director | $347,913 | +$135,829 | +64% | Filing P/S | 11 Jun 2026 |
| Mallory Morales | SVP Finance, CAO | $175,935 | +$1,917 | +1.1% | Filing P/S | 03 Feb 2026 |
| Leah R. Neufeld | Chief People Officer | $145,918 | +$18,508 | +15% | Mixed | 13 Mar 2026 |
| Harold E. Brakewood | Chief Business Officer | $52,598 | +$24,990 | +91% | Filing P/S | 03 Feb 2026 |
| Michael D. Bookman | Chief Legal Officer, Secretary | $33,261 | +$6,966 | +26% | Filing P/S | 03 Feb 2026 |
| Biren Amin | Cfo, Treasurer | $23,773 | Mixed | 12 May 2022 | ||
| Diana F. Hausman | Director | $19,862 | +$19,863 | +100% | Filing P/S | 11 Jun 2026 |
| Laurie Keating | Director | Mixed | 11 Jun 2026 | |||
| CARPENTER ROBERT J | Director | Mixed | 11 Jun 2026 | |||
| Igor Matushansky | Chief Medical Officer | Mixed | 03 Feb 2026 | |||
| Ann E. Berman | Director | Mixed | 13 Jun 2025 | |||
| Scott Barrett | Chief Medical Officer | Mixed | 15 Feb 2023 |
Recent insider transactions for Immuneering Corp
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Benjamin J. Zeskind | IMRX | Class A Common Stock | Purchase | 0.1% | $10,948 | $4.56 | 2,400 | 2,315,252 | 23 Jun 2026 | Direct |
| Brett Matthew Hall | IMRX | Class A Common Stock | Purchase | 1.6% | $25,045 | $4.15 | 6,035 | 382,531 | 15 Jun 2026 | Direct |
| Thomas J. Schall | IMRX | Stock Option | Award | 33,350 | 33,350 | 11 Jun 2026 | Direct | |||
| Diana F. Hausman | IMRX | Stock Option | Award | 33,350 | 33,350 | 11 Jun 2026 | Direct | |||
| Carpenter Robert J | IMRX | Stock Option | Award | 33,350 | 33,350 | 11 Jun 2026 | Direct | |||
| Laurie B. Keating | IMRX | Stock Option | Award | 33,350 | 33,350 | 11 Jun 2026 | Direct | |||
| Peter Feinberg | IMRX | Stock Option | Award | 33,350 | 33,350 | 11 Jun 2026 | Direct | |||
| Leah R. Neufeld | IMRX | Class A Common Stock | Award | 14% | 3,628 | 29,598 | 13 Mar 2026 | Direct | ||
| Michael D. Bookman | IMRX | Stock Option | Award | 176,000 | 176,000 | 03 Feb 2026 | Direct | |||
| Harold E. Brakewood | IMRX | Stock Option | Award | 140,000 | 140,000 | 03 Feb 2026 | Direct | |||
| Brett Matthew Hall | IMRX | Stock Option | Award | 344,000 | 344,000 | 03 Feb 2026 | Direct | |||
| Mallory Morales | IMRX | Stock Option | Award | 140,000 | 140,000 | 03 Feb 2026 | Direct | |||
| Leah R. Neufeld | IMRX | Stock Option | Award | 140,000 | 140,000 | 03 Feb 2026 | Direct | |||
| Benjamin J. Zeskind | IMRX | Stock Option | Award | 688,000 | 688,000 | 03 Feb 2026 | Direct | |||
| Igor Matushansky | IMRX | Stock Option | Award | 140,000 | 140,000 | 03 Feb 2026 | Direct | |||
| Harold E. Brakewood | IMRX | Class A Common Stock | Purchase | 90.5% | $24,990 | $4.76 | 5,250 | 11,050 | 16 Jan 2026 | Direct |
| Thomas J. Schall | IMRX | Class A Common Stock | Purchase | 40.9% | $101,041 | $4.67 | 21,645 | 74,530 | 15 Jan 2026 | Direct |
| Brett Matthew Hall | IMRX | Class A Common Stock | Purchase | 0.61% | $10,502 | $4.57 | 2,298 | 376,496 | 15 Jan 2026 | Direct |
| Leah R. Neufeld | IMRX | Class A Common Stock | Purchase | 11.2% | $10,906 | $4.15 | 2,626 | 25,970 | 13 Jan 2026 | Direct |
| Peter Feinberg | IMRX | Class A Common Stock | Purchase | 17.3% | $86,904 | $4.35 | 20,000 | 135,441 | 12 Jan 2026 | General Partner of S4K Investments LLC. |
| Laurie B. Keating | IMRX | Stock Option | Award | 7,888 | 7,888 | 01 Jan 2026 | Direct | |||
| Peter Feinberg | IMRX | Stock Option | Award | 7,888 | 7,888 | 01 Jan 2026 | Direct | |||
| Peter Feinberg | IMRX | Class A Common Stock | Purchase | 5.02% | $50,025 | $6.67 | 7,500 | 156,766 | 03 Oct 2025 | Direct |
| Mallory Morales | IMRX | Class A Common Stock | Purchase | 1.1% | $1,917 | $6.39 | 300 | 27,533 | 01 Oct 2025 | Direct |
| Leah R. Neufeld | IMRX | Class A Common Stock | Purchase | 3.55% | $5,103 | $6.38 | 800 | 23,344 | 01 Oct 2025 | Direct |
| Michael D. Bookman | IMRX | Class A Common Stock | Purchase | 26.5% | $6,966 | $6.83 | 1,020 | 4,870 | 01 Oct 2025 | Direct |
| Peter Feinberg | IMRX | Class A Common Stock | Purchase | 5.29% | $52,730 | $7.03 | 7,500 | 149,266 | 30 Sep 2025 | Direct |
| Peter Feinberg | IMRX | Class A Common Stock | Purchase | 3.66% | $35,900 | $7.18 | 5,000 | 141,766 | 29 Sep 2025 | Direct |
| Leah R. Neufeld | IMRX | Class A Common Stock | Award | 110.1% | 11,815 | 22,544 | 15 Sep 2025 | Direct | ||
| Mallory Morales | IMRX | Class A Common Stock | Award | 113.8% | 14,497 | 27,233 | 15 Sep 2025 | Direct | ||
| Brett Matthew Hall | IMRX | Class A Common Stock | Award | 4.14% | 14,880 | 374,198 | 15 Sep 2025 | Direct | ||
| Diana F. Hausman | IMRX | Class A Common Stock | Purchase | $10,874 | $3.62 | 3,000 | 3,000 | 02 Jul 2025 | By spouse | |
| Diana F. Hausman | IMRX | Class A Common Stock | Purchase | $8,989 | $3.60 | 2,500 | 2,500 | 02 Jul 2025 | Direct | |
| Leah R. Neufeld | IMRX | Class A Common Stock | Purchase | 6.98% | $2,499 | $3.57 | 700 | 10,729 | 02 Jul 2025 | Direct |
| Benjamin J. Zeskind | IMRX | Class A Common Stock | Purchase | 0.3% | $24,792 | $3.53 | 7,015 | 2,312,852 | 02 Jul 2025 | Direct |
| Benjamin J. Zeskind | IMRX | Class A Common Stock | Purchase | 0.13% | $10,087 | $3.38 | 2,985 | 2,305,837 | 01 Jul 2025 | Direct |
| Thomas J. Schall | IMRX | Class A Common Stock | Purchase | 21.9% | $34,788 | $3.66 | 9,500 | 52,885 | 27 Jun 2025 | Direct |
* marks a reported price that did not pass the local price check.